Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.
Vicore Pharma Holding AB announced a directed share issue to raise approximately USD 40 million through an accelerated bookbuilding process targeting institutional investors. The proceeds will primarily fund the expansion of the Phase 2b ASPIRE trial for buloxibutid, enhancing its potential as a disease-modifying treatment for IPF. This strategic move aims to strengthen Vicore’s financial position, diversify its shareholder base, and support future clinical and commercial activities.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a pharmaceutical company focused on developing innovative treatments for rare diseases. Its lead program, buloxibutid, is an oral small molecule AT2 receptor agonist aimed at treating idiopathic pulmonary fibrosis (IPF). The company is actively engaged in clinical trials and has received Orphan Drug and Fast Track designation from the FDA.
Average Trading Volume: 671,384
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.38B
See more data about VICO stock on TipRanks’ Stock Analysis page.